Funding for this research was provided by:
Novo Nordisk Fonden (DK) Tripartite Immunometabolism Consortium (NNF15CC0018486)
Received: 8 July 2019
Accepted: 27 September 2019
First Online: 5 October 2019
Ethics approval and consent to participate
: The ADDITION-PRO study was approved by the Ethical Committee in the Central Danish Region (No. 20000183). Written informed consents were obtained from all participants prior to the examination.
: Not applicable.
: TL holds shares in Novo Nordisk. All other authors declare that they have no competing interests.